Moderna Stock Surges on mRNA Pipeline Momentum: Is It a Long-Term Buy Amid Vaccine Challenges?

Moderna (NASDAQ:MRNA) gains $2.9 billion as investors pile into flu push, beating 2025 revenue

NEW YORK, July 2, 2026, 18:06 (EDT) Moderna, Inc. (NASDAQ:MRNA) last changed hands at $79.76 in after-hours, up $7.36, or 10.2%. That’s about $2.9 billion added in market cap on the day. Nasdaq will be closed on Friday, July 3, 2026, for Independence Day observed. U.S. stocks will have their last trading session before the…

Moderna stock jumps as pipeline progress and flu shot data lift sentiment

Moderna Inc. (MRNA) shares rose 9.2% on Thursday, making the biotechnology company one of the top performers in the S&P 500. Investors responded positively to new pipeline updates, encouraging influenza vaccine data, and favorable analyst commentary.The stock extended its recent rally after climbing to a new annual high on Wednesday. At one point, shares gained nearly 12% as investors welcomed the company's latest Science Day presentation and pr…

Moderna Stock Surges on mRNA Pipeline Momentum: Is It a Long-Term Buy Amid Vaccine Challenges?

Moderna's stock surged over 10% as investors responded positively to its expanding mRNA pipeline, despite ongoing challenges in the post-COVID landscape and mixed analyst opinions on long-term growth.